相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomised Phase 1 clinical trials in oncology
Alexia Iasonos et al.
BRITISH JOURNAL OF CANCER (2021)
TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis
M. Cole et al.
TRIALS (2021)
Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
Andre van der Westhuizen et al.
MEDICINE (2020)
Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019
Gillian Gresham et al.
JAMA NETWORK OPEN (2020)
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
Paolo Chiodini et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
How to design a dose-finding study using the continual reassessment method
Graham M. Wheeler et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Guide to the statistical analysis plan
Ian Yuan et al.
PEDIATRIC ANESTHESIA (2019)
Using simulation studies to evaluate statistical methods
Tim P. Morris et al.
STATISTICS IN MEDICINE (2019)
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination
Gordon W. Blair et al.
INTERNATIONAL JOURNAL OF STROKE (2018)
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
Athimalaipet Ramanan et al.
BMC RHEUMATOLOGY (2018)
Guidelines for the Content of Statistical Analysis Plans in Clinical Trials
Carrol Gamble et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
Christina Yap et al.
CLINICAL CANCER RESEARCH (2017)
Embracing model-based designs for dose-finding trials
Sharon B. Love et al.
BRITISH JOURNAL OF CANCER (2017)
CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement
Sunita Vohra et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement
Sunita Vohra et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3+3 Design for Practical Phase I Trials
Yuan Ji et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Finding Designs: The Role of Convergence Properties
Assaf P. Oron et al.
(2011)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in Phase I dose-finding studies
Alexia Iasonos et al.
CLINICAL TRIALS (2008)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Better reporting of harms in randomized trials: An extension of the CONSORT statement
JPA Ioannidis et al.
ANNALS OF INTERNAL MEDICINE (2004)
分享论文
